In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction — a measure of the heart’s ability to pump blood — the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing ‘gold standard’ therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported.